Skip to content
The Policy VaultThe Policy Vault

Imkeldi (imatinib oral solution) — Medica

Myeloid/lymphoid neoplasms with eosinophilia

Initial criteria

  • age ≥ 18 years
  • Tumor has an ABL1 rearrangement OR tumor has FIP1L1-PDGFRA or PDGFRB rearrangement

Approval duration

1 year